General Information
We accelerate medicines to patients using biosimulation software and technology to transform traditional drug discovery and development.
Biosimulation is a powerful technology used to conduct virtual trials using virtual patients to better understand how drugs behave in different individuals. Biopharmaceutical companies use our proprietary biosimulation software throughout drug discovery and development to inform critical decisions that not only save significant time and money but also advance drug safety and efficacy, improving millions of lives each year.
(Note: The Certara deal was upsized at pricing: 29.1 million shares were priced at $23, up from 24.4 million shares at $19 to $22 in the prospectus.)
Employees: 899
Founded: 2017
Contact Information
Address 100 Overlook Center, Suite 101, Princeton, NJ 08540, US
Phone Number (609) 716-7900
Web Address http://www.certara.com
View Prospectus: Certara
Financial Information
Market Cap
Revenues $232.7 mil (last 12 months)
Net Income $1.99 mil (last 12 months)
IPO Profile
Symbol CERT
Exchange NASDAQ
Shares (millions): 29.1
Price range $23.00 - $23.00
Est. $ Volume $669.3 mil
Manager / Joint Managers Jefferies/ Morgan Stanley/ BofA Securities/ Credit Suisse/ Barclays/ William Blair
CO-Managers -
Expected To Trade: 12/11/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change